Female sexual arousal disorder (FSAD) is a common disorder encountered in clinical practice, but no drugs for FSAD have been approved. In this Review, Schoen and Bachmann discuss the use of sildenafil citrate, a phosphodiesterase type-5 inhibitor, for FSAD treatment. They provide the rationale for treatment, and discuss results of sildenafil citrate from past clinical studies in women with FSAD.
- Corina Schoen
- Gloria Bachmann